We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck announced it has entered into a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.